CRISPR-based gene therapy represents one of the most promising frontiers of precision medicine, especially in the treatment of mitochondrial diseases, hitherto considered incurable. This article by Nicolás Jouve analyses the latest scientific advances that have made it possible to overcome some of the main technical and ethical barriers associated with mitochondrial DNA editing, opening a promising pathway towards potential personalized therapies that could transform the prognosis of these diseases.

In a previous article, we discussed innovations in CRISPR-Cas9 technology to improve the outcomes of its use in the direct modification of DNA molecules in order to correct or eliminate genetic defects in carriers. Gene therapy is unquestionably an application of considerable interest and, although many clinical trials are currently underway, the results are still limited in terms of therapies accepted by international drug agencies (FDA, EMA, etc.).

At present, this technology is focused on monogenic diseases or on disorders that are mainly due to alterations in the DNA of a specific gene within the nuclear genome, and does not yet offer the reliability and safety required to edit and correct human genes with the necessary precision. Furthermore, the possibility of correcting so-called mitochondrial diseases has not been addressed.

The original technique has gradually given way to innovative methods resulting in increased precision and efficiency. Nevertheless, further research is needed, and there is still a long way to go before CRISPR-Cas9 can be used to edit and restore DNA for clinical applications in humans. The biggest technical hurdle from which ethical consequences derive continues to be the “cleanliness” and efficiency of the molecular mechanism applied, mainly due to two types of complications.

The first of these is the risk of affecting regions beyond the intended DNA target and generating changes, including base insertions or deletions (indels) at the target site. One determining factor is the type of DNA cut, and complementary or non-complementary single-stranded regions may remain at the ends of the break. In the first case, homology-directed repair (HDR) — also known as homologous recombination (HR) — may occur, and in the second, non-homologous end-joining (NHEJ). The outcome will differ, since NHEJ is prone to introducing indels and, as a consequence, changes in DNA information. This leads to functional gene inactivation, which conversely may be of interest in some cases (interference CRISPR). HR is preferable when it comes to substituting some of the bases of the altered message with the correct ones, which is what the term “gene editing” refers to.

The second complication is due to unintended actions on other regions of the genome, known as “off-target” effects, which can be unpredictable. Therefore, the primary objective of all clinical trials aimed at developing treatments for certain conditions using CRISPR is to test the efficacy and safety of the technology by restricting its action to the specific nucleotide bases of the gene targeted for modification or inactivation.

We must also bear in mind the difficulty of targeting the precise location within a genome of 3.175 billion DNA base pairs, and of the order of 21,000 genes, where the goal is to affect just a single detail on one of them without touching or altering the rest of the genetic information. This precision is possible thanks to recognition of the target sequence through the use of a guide RNA molecule, which is designed to pair with the target gene by complementary base pairing. The Cas9 enzyme is then responsible for cutting the DNA, after which the cell’s repair mechanisms will fix the break in the targeted region. The main technological modifications have been directed at improving the precision of target region recognition and its subsequent repair in the desired direction.

The technology to be applied is subsequent to the knowledge (sometimes partial) of the pathology to be corrected, but fortunately, thanks to the Human Genome Project, we now know the nucleotide base sequence of the genes involved. Several thousand diseases caused by mutations affecting the nucleotide bases of a gene have been described. Hemophilia, cystic fibrosis, sickle cell anemia, β-thalassemia, achondroplasia, cholesterolemia, neurofibromatosis, etc., are just some of the examples of monogenic diseases due to the alteration of one or a few bases (of a different gene in each case), on which the applications of CRISPR-cas9 have initially been focused. The technology developed so far fundamentally aims to correct or eliminate the DNA of the gene responsible for the disease, without ruling out other types of actions, such as the activation of an alternative gene, given the existence of duplicated genes in the genome that must fulfil the same functions in different tissue types or developmental stages. In any case, the technology to be applied is very selective with respect to the target DNA region, so simultaneous action on several regions, as would be the case in polygenic diseases, has been discounted for the time being.

Also on the horizon of gene therapy are diseases due to alterations in extranuclear DNA, also known as extrachromosomal or mitochondrial DNA (mtDNA). This is a small percentage of DNA located in the mitochondria of cells, which is transmitted only through the maternal line, through the cytoplasm of the egg. Despite its small size compared to the nuclear genome, mtDNA is of great functional importance, as it is involved in cellular metabolism. This circular DNA consists of around 16,500 base pairs and contains 37 genes. In fact, mtDNA is a relic of the prokaryotic genome that, via endosymbiosis, made the evolution from prokaryotic to eukaryotic cells possible. After this evolutionary leap, mitochondria became the “powerhouses” of the cell.

There are some serious human diseases caused by alterations in the few genes contained in the mtDNA. Among them are some considered incurable and that affect the central nervous system, such as Leigh syndrome, a progressive degeneration of the nervous system that manifests in the first few months of life; Leber hereditary optic neuropathy, which affects sight; Kearnes-Sayre syndrome, which appears before the age of 20 and affects sight and hearing; MERRF syndrome, which affects the nervous system, muscles, and other areas of the body; and MELAS syndrome, which affects various areas including the brain and muscles; etc. Despite the interest in mitochondrial genetics, the mitochondrial double membrane has proven to be a formidable barrier to genetic engineering.

Trying to correct mtDNA is a difficult challenge that has been impossible to overcome with CRISPR-Cas9 technology until now. One characteristic of mtDNA is its multicopy nature, meaning that mutations often occur in a state known as “heteroplasmy”, where both mutant and normal mtDNA are present in the same cell. The normal mtDNA can functionally compensate for the mutant mtDNA until an expression threshold is reached, beyond which disease symptoms begin to manifest.

Below are two advances developed to improve the precision and expand the use of the technique in mtDNA.

Single-base substitution techniques

The original CRISPR-Cas9 technique was based on the recognition and cutting of DNA in the region responsible for the alteration to be corrected. Following recognition of the target DNA sequence by throwing guide RNA “darts” accompanied by the Cas9 enzyme, DNA breakage and repair is induced. As we mentioned in a previous article, prime editing avoids cutting both chains, and acts on only one of them. The difference in terms of errors in the modification and effectiveness of the method is substantial and side effects are considerably reduced.

In any case, the tendency is to produce the smallest possible change in the DNA targeted by the CRISPR application. Efforts are therefore being made to reduce the effect of the technology and circumvent the breakage of both DNA strands (double-strand breaks, DSB), to avoid the insertion or deletion of bases (indels). To do this, in addition to prime editing, some modifications to the technique have been developed that allow changes to be reduced to a single base substitution. Accordingly, two modifications of the technique have been developed to achieve two kinds of changes: cytosine base editors (CBEs) and adenine base editors (ABEs).[1, 2] Together, all four transition mutations (C to T, T to C, A to G, and G to A) can be achieved with the available CRISPR-Cas transcription systems, although modifications have had to be made to the Cas9 nuclease that is applied in the different cases. It should be noted that many of the pathogenic point mutations can, in principle, be reversed by ABE to reduce editing by converting an A-T base pair into a G-C base pair.

Extending gene editing to mitochondrial DNA

Editing in mtDNA poses a challenge for researchers who are attempting to apply this technology to the case of mitochondrial diseases.

CRISPR-Cas9 cannot cross the mitochondrial membrane, so it has not been possible to propose this type of therapy until now. Recently, a research team from the Netherlands successfully achieved the first milestones in the editing of mtDNA.[3] Scientists have discovered that mtDNA can be modified by importing gene editing proteins that target specific DNA sequences. Mitochondria-targeted nucleases specifically cleave and eliminate mutant mtDNA in heteroplasmic cells and in animal models, as well as in some organoids

For this purpose, base editors have been adapted to modify mtDNA via precise C to T or A to G transitions. Researchers have harnessed this technology to develop mitochondrial disease models and therapeutic strategies to correct them in organoids. To this end, organoid lines were created with different modifications to study various mtDNA editing strategies to analyze their possible corrective effects on mitochondrial diseases. These models allow us to study the functional consequences of the changes produced in a certain position of the mtDNA. For example, a pathogenic mutation was induced by a change from G to A at position 15150 of mtDNA, which showed functional effects on ATP production in human adult liver organoids. Similarly, correction of the T to C mutation at position 4291 of the mtDNA in a fibroblast model derived from a patient with Gitelman syndrome, an inherited pediatric pathology that affects the kidneys due to salt and water loss, improved mitochondrial function. These studies thus demonstrated the potential of mitochondrial base editing to generate unique in vitro models for the study of mitochondrial diseases and to functionally correct DNA mutations of these organelles for future therapeutic purposes.

Other innovations of great interest were introduced in this research, such as the use of lipid nanoparticles for the efficient delivery of mRNA mitochondrial base editors. Nanoparticles have become the most widely used non-viral in vivo delivery vectors for introducing the molecules involved in gene therapy.

The researchers concluded that mtDNA base editing is a promising and precise gene editing tool for creating and correcting mitochondrial mutations in primary patient-derived cell types, making it an exciting prospect for future research and development in mitochondrial medicine. The modification of mtDNA is already a reality that promises to revolutionize the field of mitochondrial genetics.[4]

Upon learning the potential of these research studies, relatively recent cases related to mitochondrial diseases come to mind that, due to their severity and irreversibility, sparked major bioethical debates. One such case is that of baby Charlie Gard, born in London in August 2016, who remained connected to life support machines as he suffered from mitochondrial DNA depletion syndrome. Against the wishes of his parents and contrary to elementary personalist bioethics, the doctors who treated him at Great Ormond Children’s Hospital in London were of the opinion that the baby would likely experience irreversible brain damage, with no prospect of improvement. This led them to conclude that the mechanical ventilation keeping him alive should be withdrawn so that he could “die with dignity”. This decision was ratified by a judge who ruled that it would be in Charlie’s best interest to withdraw medical support. The case ignited a huge international debate, going against the expert opinion of other clinicians and ignoring the support of Pope Francis who intervened on behalf of the parents’ wishes and who rightly said that the honorable thing would be to respect the parental rights and exhaust all possibilities to prolong the life of the child.

It seems like a big mistake, as so often happens in bioethical issues, to say that actively or passively causing or hastening death leads to a dignified death, or to try to justify the decision to end the patient’s life as being in the “best interest” of the baby. Death if induced cannot be considered dignified and if there is no suffering, as in the case of Charlie and so many others in which palliative care can be applied, it ceases to be a compassionate death to become an act of euthanasia.

While it is still too early to meet the requirements for correcting mitochondrial diseases, the good news is that the first steps are being taken to achieve this. At the same time, new breakthroughs such as prime editing and base editors are improving the outcomes of CRISPR techniques by increasing efficiency and reducing errors.

Nicolás Jouve

Professor Emeritus of Genetics at the University of Alcalá

Member of the Bioethics Observatory of the Catholic University of Valencia

 

References:

[1] Kurt IC, Zhou R, Iyer S, et al. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat Biotechnol. 2021;39(1):41-46.

[2] Kantor A, McClements ME, MacLaren RE. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int J Mol Sci. 2020 28;21(17):6240.

[3] Joore IP, Shehata S, Muffels I, et al. Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors. PLoSBiol 2025;23(6): e3003207.

[4] Shoop WK, Bacman SR, Barrera-Paez J.D. et al. Mitochondrial gene editing. Nat Rev Methods Primers 2023;3:19.

 

 

 

Share This Story, Choose Your Platform!